BioWorld

Nov. 5, 2002

View Archived Issues

With DN-101 In Phase II/III Trial, Novacea Closes $36M Series B

Novacea Inc. pulled in $36 million in its Series B round of financing, a sum the company says is validated by its drug in a later-stage trial and a solid group at the top. (BioWorld Today) Read More

Alexion Data Point To Potential For Treatment Over Long Term

Read More

Zinc-Finger Transcription Factor Switches On Body's Gene For Expression Of Multiple Proteins

Read More

FDA Tells Biogen To Clean Up Avonex Advertising Claims

Read More

Gilead Presents Combination Hepsera, Lamivudine Data

Read More

Other News To Note

Read More